NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 180 filers reported holding NEKTAR THERAPEUTICS in Q2 2016. The put-call ratio across all filers is 0.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $61,583 | +30386.6% | 87,600 | -1.9% | 0.00% | -66.7% |
| Q4 2022 | $202 | -99.9% | 89,300 | -0.2% | 0.01% | -25.0% |
| Q3 2022 | $286,000 | -15.6% | 89,500 | -0.7% | 0.01% | -11.1% |
| Q2 2022 | $339,000 | -18.9% | 90,100 | +0.4% | 0.01% | -10.0% |
| Q1 2022 | $418,000 | -65.3% | 89,700 | +0.4% | 0.01% | -61.5% |
| Q4 2021 | $1,206,000 | +43.2% | 89,300 | +90.4% | 0.03% | +30.0% |
| Q3 2021 | $842,000 | +3.7% | 46,900 | -0.8% | 0.02% | 0.0% |
| Q2 2021 | $812,000 | -14.2% | 47,300 | 0.0% | 0.02% | -20.0% |
| Q1 2021 | $946,000 | +24.1% | 47,300 | +5.6% | 0.02% | +13.6% |
| Q4 2020 | $762,000 | +2.7% | 44,800 | +0.2% | 0.02% | -35.3% |
| Q3 2020 | $742,000 | -27.8% | 44,700 | +0.7% | 0.03% | -44.3% |
| Q2 2020 | $1,028,000 | +35.3% | 44,400 | +4.2% | 0.06% | +10.9% |
| Q1 2020 | $760,000 | -17.4% | 42,600 | 0.0% | 0.06% | +19.6% |
| Q4 2019 | $920,000 | +214.0% | 42,600 | +389.7% | 0.05% | +206.7% |
| Q2 2019 | $293,000 | -5.2% | 8,700 | -5.4% | 0.02% | 0.0% |
| Q1 2019 | $309,000 | +3.3% | 9,200 | +1.1% | 0.02% | -11.8% |
| Q4 2018 | $299,000 | -51.5% | 9,100 | -9.9% | 0.02% | -34.6% |
| Q3 2018 | $616,000 | +32.8% | 10,100 | +6.3% | 0.03% | +23.8% |
| Q2 2018 | $464,000 | -55.4% | 9,500 | -3.1% | 0.02% | -56.2% |
| Q1 2018 | $1,041,000 | -74.3% | 9,800 | -85.5% | 0.05% | -73.9% |
| Q4 2017 | $4,043,000 | +166.2% | 67,700 | +7.0% | 0.18% | +159.2% |
| Q3 2017 | $1,519,000 | +22.9% | 63,300 | +0.2% | 0.07% | +16.4% |
| Q2 2017 | $1,236,000 | -16.0% | 63,200 | +0.8% | 0.06% | -17.6% |
| Q1 2017 | $1,472,000 | +95.5% | 62,700 | +2.1% | 0.07% | +89.7% |
| Q4 2016 | $753,000 | -27.5% | 61,400 | +1.7% | 0.04% | -29.1% |
| Q3 2016 | $1,038,000 | +21.0% | 60,400 | +0.2% | 0.06% | +22.2% |
| Q2 2016 | $858,000 | +3.6% | 60,300 | +0.2% | 0.04% | +4.7% |
| Q1 2016 | $828,000 | -16.7% | 60,200 | +2.0% | 0.04% | -14.0% |
| Q4 2015 | $994,000 | +55.6% | 59,000 | +1.2% | 0.05% | +51.5% |
| Q3 2015 | $639,000 | -12.6% | 58,300 | -0.2% | 0.03% | -5.7% |
| Q2 2015 | $731,000 | – | 58,400 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |